▁Introduction 10.375
: 6.5078125
<0x0A> 4.01953125
B 4.46875
rit 3.337890625
ish 0.42822265625
▁bi 8.09375
ote 3.583984375
chn 0.884765625
ology 0.0745849609375
▁company 1.912109375
▁X 7.85546875
Y 5.08984375
Z 0.74755859375
▁has 2.86328125
▁announced 2.185546875
▁encourag 12.6015625
ing 0.004367828369140625
▁find 3.935546875
ings 0.0005035400390625
▁from 0.8955078125
▁the 2.8046875
▁final 4.078125
▁stage 1.7822265625
▁of 0.058685302734375
▁clin 2.548828125
ical 0.0005178451538085938
▁tri 0.1590576171875
als 0.0025539398193359375
▁for 1.1328125
▁its 0.76513671875
▁ground 4.53125
bre 0.9736328125
aking 0.0003421306610107422
▁cancer 2.744140625
▁drug 2.578125
. 1.21484375
▁The 1.41015625
▁drug 0.99365234375
, 0.69384765625
▁c 5.7734375
oden 1.66796875
amed 0.0003032684326171875
▁T 3.783203125
um 6.671875
oro 6.984375
C 5.0546875
ure 2.060546875
, 0.4619140625
▁has 1.576171875
▁demonstrated 3.06640625
▁significant 2.958984375
▁effic 2.08984375
acy 0.00028204917907714844
▁and 2.095703125
▁a 2.65234375
▁favor 2.943359375
able 0.00138092041015625
▁safety 0.2236328125
▁profile 0.06463623046875
▁in 0.52294921875
▁tre 3.634765625
ating 0.00024437904357910156
▁various 4.5078125
▁types 0.6826171875
▁of 0.011932373046875
▁cancer 0.6337890625
. 1.0107421875
▁However 5.55078125
, 0.01093292236328125
▁while 4.91796875
▁the 0.88720703125
▁news 4.4375
▁has 1.9384765625
▁generated 4.0859375
▁excitement 1.9287109375
▁and 2.572265625
▁hope 2.6484375
▁among 1.6220703125
▁patients 1.8447265625
, 1.0849609375
▁anal 6.0078125
yst 0.0012693405151367188
s 0.004421234130859375
▁are 1.48828125
▁advis 5.1875
ing 0.0005846023559570312
▁a 5.2265625
▁measured 4.97265625
▁approach 0.646484375
▁when 3.763671875
▁evalu 3.685546875
ating 0.00021398067474365234
▁the 0.297119140625
▁potential 2.546875
▁market 3.828125
▁impact 1.927734375
▁and 3.333984375
▁long 3.244140625
- 0.042755126953125
term 0.006317138671875
▁vi 2.51953125
ability 0.00043582916259765625
▁of 0.05438232421875
▁the 0.51513671875
▁drug 0.4482421875
. 0.1448974609375
<0x0A> 0.2447509765625
Pos 7.109375
itive 0.08660888671875
▁results 1.828125
▁from 1.0048828125
▁clin 2.802734375
ical 0.0015954971313476562
▁tri 0.06268310546875
als 4.9233436584472656e-05
: 5.828125
<0x0A> 0.468505859375
T 3.765625
um 0.08551025390625
oro 0.020233154296875
C 0.0025615692138671875
ure 0.0005521774291992188
' 3.873046875
s 0.0025806427001953125
▁positive 2.5625
▁out 4.41796875
comes 0.0088043212890625
▁stem 3.099609375
▁from 0.1387939453125
▁compreh 7.2109375
ensive 0.00386810302734375
▁Ph 3.94140625
ase 0.0013055801391601562
▁III 1.2822265625
▁clin 0.814453125
ical 0.00060272216796875
▁tri 0.12548828125
als 7.62939453125e-06
, 1.9345703125
▁conducted 2.61328125
▁on 3.333984375
▁a 2.44140625
▁large 2.77734375
▁coh 3.357421875
ort 1.0371208190917969e-05
▁of 0.04559326171875
▁patients 0.55810546875
▁across 2.380859375
▁different 3.361328125
▁cancer 1.267578125
▁types 0.1295166015625
. 0.541015625
▁The 0.76513671875
▁drug 1.689453125
▁exhib 5.54296875
ited 0.10552978515625
▁remarkable 4.1015625
▁tum 6.37890625
or 0.01263427734375
▁regression 2.2578125
▁rates 2.58984375
, 2.0078125
▁showing 5.05078125
▁promise 3.296875
▁as 2.119140625
▁a 0.2281494140625
▁potential 1.8623046875
▁break 3.794921875
through 0.0082244873046875
▁in 1.0068359375
▁cancer 1.49609375
▁treatment 0.377197265625
. 0.2164306640625
▁With 5.55078125
▁its 3.60546875
▁unique 4.35546875
▁mechanism 1.5673828125
▁of 0.06011962890625
▁action 0.020843505859375
▁target 4.6875
ing 0.058624267578125
▁specific 3.65234375
▁cancer 1.482421875
▁markers 5.52734375
, 0.46875
▁T 1.14453125
um 0.0019464492797851562
oro 0.003936767578125
C 0.0010938644409179688
ure 0.0004019737243652344
▁offers 3.744140625
▁a 0.97607421875
▁novel 2.326171875
▁approach 1.357421875
, 5.125
▁differenti 5.8125
ating 0.16552734375
▁it 0.6044921875
▁from 0.044921875
▁conventional 3.130859375
▁ther 2.080078125
ap 0.0499267578125
ies 1.3947486877441406e-05
▁commonly 6.125
▁used 0.2215576171875
▁today 2.80078125
. 0.26904296875
<0x0A> 0.53466796875
E 4.15234375
ffic 0.833984375
acy 0.0119476318359375
▁and 0.9716796875
▁safety 0.16845703125
▁profile 1.248046875
: 0.1802978515625
<0x0A> 0.011260986328125
Not 6.77734375
ably 0.332275390625
, 0.0099945068359375
▁T 1.1767578125
um 0.0007166862487792969
oro 0.001956939697265625
C 0.0007281303405761719
ure 0.0004425048828125
▁demonstrated 2.14453125
▁effic 3.720703125
acy 1.430511474609375e-05
▁across 2.13671875
▁a 0.92724609375
▁wide 1.345703125
▁range 0.37841796875
▁of 0.002899169921875
▁cancer 0.6669921875
▁types 0.1304931640625
, 0.580078125
▁including 0.81201171875
▁breast 1.978515625
, 0.2386474609375
▁lung 1.2685546875
, 0.06976318359375
▁pan 2.826171875
cre 0.0002142190933227539
atic 0.364501953125
, 0.11700439453125
▁and 1.2412109375
▁col 2.544921875
ore 0.0030040740966796875
ct 8.821487426757812e-05
al 0.0009546279907226562
▁cancer 1.3310546875
. 0.258056640625
▁Scient 7.98828125
ific 1.150390625
▁evidence 2.21875
▁highlight 5.6484375
s 0.435791015625
▁the 1.021484375
▁drug 1.0302734375
' 0.04034423828125
s 0.0003523826599121094
▁ability 1.673828125
▁to 0.006381988525390625
▁in 2.990234375
hib 0.0129852294921875
it 0.0014209747314453125
▁cancer 2.015625
▁cell 0.94921875
▁pro 1.2548828125
l 0.00783538818359375
ifer 0.00011539459228515625
ation 0.0005965232849121094
▁and 0.94580078125
▁indu 2.302734375
ce 0.005939483642578125
▁apo 0.75244140625
pt 0.00010192394256591797
osis 0.0139923095703125
▁through 4.13671875
▁a 2.3515625
▁series 4.75390625
▁of 0.0009598731994628906
▁well 5.796875
- 0.0171051025390625
defined 1.482421875
▁bi 4.03515625
ological 0.2064208984375
▁path 1.3349609375
ways 0.001537322998046875
. 0.2069091796875
▁Moreover 3.25390625
, 0.0002849102020263672
▁the 0.84765625
▁side 7.09765625
▁effects 0.59521484375
▁observed 2.099609375
▁were 2.076171875
▁relatively 3.61328125
▁m 0.3994140625
ild 0.0008454322814941406
, 0.9111328125
▁present 5.87890625
ing 0.06500244140625
▁a 1.11328125
▁less 4.9375
▁bur 4.7890625
dens 0.10223388671875
ome 5.888938903808594e-05
▁treatment 0.9599609375
▁option 0.97265625
▁compared 2.072265625
▁to 0.1251220703125
▁current 2.93359375
▁available 5.22265625
▁alternatives 3.076171875
. 0.08795166015625
<0x0A> 0.268798828125
Anal 4.93359375
yst 0.039459228515625
s 0.59619140625
▁remain 3.919921875
▁c 0.79052734375
aut 7.236003875732422e-05
ious 0.2320556640625
: 0.234619140625
<0x0A> 0.0022983551025390625
Wh 1.8203125
ile 0.0004467964172363281
▁the 0.82958984375
▁results 2.494140625
▁are 1.7587890625
▁und 5.47265625
ou 0.8173828125
bt 0.0009503364562988281
edly 0.0086669921875
▁prom 0.8671875
ising 0.0002143383026123047
, 0.11004638671875
▁anal 1.2607421875
yst 5.6624412536621094e-05
s 0.00281524658203125
▁ca 2.857421875
ution 0.0010662078857421875
▁against 1.5869140625
▁over 1.7646484375
ly 2.123046875
▁optim 0.346923828125
istic 0.005687713623046875
▁expect 0.81298828125
ations 3.3974647521972656e-05
▁at 4.453125
▁this 0.116455078125
▁early 1.5400390625
▁stage 0.07330322265625
. 0.59765625
▁Exper 5.5625
ts 0.15234375
▁emphas 4.0078125
ize 0.07421875
▁the 0.708984375
▁need 0.92919921875
▁for 0.393798828125
▁additional 2.111328125
▁scr 9.828125
ut 0.0004215240478515625
iny 0.00655364990234375
▁and 1.17578125
▁further 3.259765625
▁validation 3.86328125
▁in 2.73046875
▁larger 2.984375
, 2.06640625
▁more 1.4169921875
▁diverse 1.6572265625
▁patient 1.095703125
▁populations 0.410400390625
▁to 2.443359375
▁determine 2.58984375
▁the 0.88232421875
▁applic 6.85546875
ability 0.0007033348083496094
▁and 1.5185546875
▁market 4.1796875
▁potential 1.0341796875
▁of 0.1336669921875
▁T 0.708984375
um 0.0004620552062988281
oro 0.0014944076538085938
C 0.0005779266357421875
ure 0.000408172607421875
. 0.258056640625
▁Tri 9.9453125
als 0.5390625
▁often 7.46484375
▁face 2.71875
▁un 4.4609375
for 0.64404296875
ese 0.00482940673828125
en 0.0215911865234375
▁challeng 0.71435546875
es 5.650520324707031e-05
▁when 4.7265625
▁transition 4.484375
ing 0.007602691650390625
▁to 1.251953125
▁real 5.23046875
- 0.07916259765625
world 0.069091796875
▁settings 1.546875
, 0.310546875
▁highlight 4.28125
ing 0.00902557373046875
▁the 0.15966796875
▁importance 1.5068359375
▁of 0.017333984375
▁rig 3.76171875
orous 0.05584716796875
▁post 4.84765625
- 0.03375244140625
mark 0.84375
eting 0.0003795623779296875
▁studies 1.4775390625
▁to 1.0048828125
▁confirm 2.55859375
▁the 1.2548828125
▁drug 0.81298828125
' 0.0077972412109375
s 0.00014066696166992188
▁long 3.349609375
- 0.002857208251953125
term 0.00634765625
▁safety 1.7294921875
▁and 0.310791015625
▁effect 2.244140625
iveness 0.004863739013671875
. 0.2333984375
<0x0A> 0.2396240234375
Reg 4.87109375
ul 0.69775390625
atory 0.0168304443359375
▁hur 2.228515625
d 2.5033950805664062e-05
les 0.01534271240234375
▁and 3.203125
▁pr 4.9296875
icing 0.003993988037109375
▁concerns 1.8876953125
: 0.04754638671875
<0x0A> 0.0037708282470703125
M 5.33984375
oving 1.9326171875
▁forward 0.1702880859375
, 0.0193634033203125
▁regul 2.123046875
atory 0.1309814453125
▁appro 1.8837890625
val 4.935264587402344e-05
▁will 1.98046875
▁be 0.26953125
▁a 1.9326171875
▁critical 1.630859375
▁mil 1.064453125
estone 5.745887756347656e-05
▁for 0.54345703125
▁T 0.662109375
um 0.0002257823944091797
oro 0.000885009765625
C 0.0005373954772949219
ure 0.00016987323760986328
. 0.82861328125
▁Any 6.0078125
▁del 2.107421875
ays 0.00012826919555664062
▁or 1.310546875
▁short 6.9453125
com 0.172607421875
ings 8.463859558105469e-06
▁in 0.88720703125
▁the 0.80029296875
▁drug 1.494140625
' 0.059417724609375
s 0.0006451606750488281
▁appro 1.5224609375
val 0.0018472671508789062
▁process 0.298095703125
▁may 2.27734375
▁significantly 3.267578125
▁impact 0.755859375
▁its 0.640625
▁market 1.7373046875
▁entry 6.46484375
▁and 0.93896484375
▁ult 4.359375
imate 0.0007319450378417969
▁success 1.3662109375
. 0.1104736328125
▁Anal 4.0390625
yst 0.00171661376953125
s 0.0020656585693359375
▁also 2.064453125
▁raise 4.12890625
▁concerns 0.23193359375
▁over 1.1708984375
▁potential 2.0625
▁pr 0.427734375
icing 3.504753112792969e-05
▁strateg 5.3671875
ies 0.00021517276763916016
, 0.97021484375
▁as 2.041015625
▁the 1.208984375
▁costs 5.421875
▁associated 1.1943359375
▁with 0.00586700439453125
▁bi 6.56640625
ote 0.34228515625
chn 0.322998046875
ological 3.71875
▁break 4.29296875
through 0.00035643577575683594
s 0.04095458984375
▁can 1.5458984375
▁be 0.442626953125
▁considerable 3.86328125
. 0.2724609375
▁St 6.76171875
rik 3.4765625
ing 0.0037670135498046875
▁a 0.95947265625
▁balance 0.27978515625
▁between 0.02679443359375
▁afford 2.65234375
ability 0.1090087890625
▁for 3.666015625
▁patients 0.32861328125
▁and 0.277099609375
▁ens 5.5546875
uring 0.004146575927734375
▁a 2.54296875
▁sust 1.9130859375
ain 0.0287628173828125
able 0.0018482208251953125
▁business 2.2890625
▁model 0.021453857421875
▁for 1.5791015625
▁the 0.78857421875
▁company 0.65380859375
▁will 1.3642578125
▁be 0.37841796875
▁essential 2.6015625
▁for 1.6787109375
▁the 2.2734375
▁w 7.00390625
ides 0.01560211181640625
p 0.0031337738037109375
read 5.650520324707031e-05
▁ad 0.373046875
option 0.00016498565673828125
▁of 0.103759765625
▁this 2.888671875
▁potentially 3.470703125
▁life 0.5390625
- 0.006744384765625
s 0.67236328125
aving 0.000377655029296875
▁drug 0.9619140625
. 0.0219268798828125
<0x0A> 0.0472412109375
Comp 6.21484375
et 0.6015625
itive 0.52880859375
▁landscape 0.62548828125
▁and 2.046875
▁future 1.6962890625
▁directions 4.94140625
: 0.06622314453125
<0x0A> 0.00215911865234375
The 2.26171875
▁cancer 3.0390625
▁th 3.580078125
era 9.644031524658203e-05
pe 1.0132789611816406e-05
ut 1.3113021850585938e-05
ics 0.0916748046875
▁market 0.1900634765625
▁is 0.242919921875
▁highly 1.9453125
▁compet 0.46484375
itive 5.412101745605469e-05
, 0.45849609375
▁with 0.382568359375
▁existing 4.72265625
▁treatment 6.19921875
▁options 0.0892333984375
▁already 4.33203125
▁approved 4.46484375
▁and 1.70703125
▁in 2.1328125
▁use 1.4296875
. 0.755859375
▁To 4.80859375
▁pen 6.0859375
et 0.0013418197631835938
rate 2.586841583251953e-05
▁this 0.9248046875
▁market 0.7900390625
, 0.183349609375
▁X 0.79931640625
Y 0.0010251998901367188
Z 0.00015664100646972656
▁must 0.96435546875
▁establish 3.857421875
▁T 2.94140625
um 6.771087646484375e-05
oro 0.0005893707275390625
C 0.0003459453582763672
ure 0.0003063678741455078
' 1.306640625
s 0.0001856088638305664
▁superior 4.23046875
ity 1.0595703125
▁over 0.77783203125
▁established 3.541015625
▁ther 1.193359375
ap 0.0033855438232421875
ies 6.318092346191406e-06
. 1.6708984375
▁Furthermore 4.45703125
, 0.00016951560974121094
▁it 3.107421875
▁will 1.361328125
▁be 1.0908203125
▁cru 1.7978515625
cial 0.0008144378662109375
▁to 0.89697265625
▁assess 5.31640625
▁potential 3.013671875
▁syn 4.9609375
erg 0.07550048828125
ies 0.227783203125
▁with 1.267578125
▁complement 5.48046875
ary 0.0031223297119140625
▁treat 3.599609375
ments 3.457069396972656e-05
▁or 3.66015625
▁develop 3.533203125
▁combin 13.03125
ational 2.32421875
▁ther 0.59130859375
ap 0.02862548828125
ies 7.62939453125e-06
▁for 3.310546875
▁improved 3.078125
▁patient 1.8623046875
▁out 0.072998046875
comes 0.0001354217529296875
. 0.105224609375
▁Coll 7.01171875
abor 0.0007047653198242188
ations 0.6796875
▁with 0.5595703125
▁research 4.09375
▁bodies 4.9296875
, 1.7578125
▁health 4.48828125
care 0.26025390625
▁institutions 2.556640625
, 0.0207061767578125
▁and 0.1981201171875
▁ph 1.9384765625
arma 0.0040435791015625
ce 0.0257720947265625
ut 1.3113021850585938e-06
ical 5.2809715270996094e-05
▁companies 0.2366943359375
▁could 2.4609375
▁acceler 4.56640625
ate 5.936622619628906e-05
▁the 0.84130859375
▁drug 0.92724609375
' 0.00266265869140625
s 0.00020766258239746094
▁development 1.685546875
▁and 0.49072265625
▁enh 4.0546875
ance 0.0006518363952636719
▁its 0.1884765625
▁market 1.9248046875
▁pen 4.04296875
etr 0.0013685226440429688
ation 9.799003601074219e-05
. 0.15283203125
<0x0A> 0.11602783203125
Con 4.24609375
clusion 0.45947265625
: 0.163818359375
<0x0A> 5.10546875
B 4.4375
rit 3.064453125
ish 0.010223388671875
▁bi 0.036712646484375
ote 0.00176239013671875
ch 2.783203125
▁X 2.626953125
Y 0.0023822784423828125
Z 0.00013971328735351562
' 2.31640625
s 0.0029392242431640625
▁cancer 3.4921875
▁drug 0.287353515625
, 1.0205078125
▁T 0.3828125
um 0.0007500648498535156
oro 0.0024280548095703125
C 0.0006198883056640625
ure 0.0001308917999267578
, 0.042694091796875
▁has 0.326904296875
▁displayed 4.6796875
▁encourag 1.5849609375
ing 0.00042319297790527344
▁results 0.82080078125
▁in 1.029296875
▁Ph 1.4765625
ase 0.0003139972686767578
▁III 0.02105712890625
▁clin 0.09271240234375
ical 0.0001773834228515625
▁tri 0.01427459716796875
als 4.76837158203125e-07
, 1.4833984375
▁demonstr 2.689453125
ating 0.00013518333435058594
▁impress 4.25390625
ive 0.0008492469787597656
▁effic 0.11712646484375
acy 8.463859558105469e-06
▁against 4.46875
▁various 1.236328125
▁cancer 1.5341796875
▁types 0.052978515625
▁with 5.3359375
▁manage 7.92578125
able 0.0092010498046875
▁side 0.17236328125
▁effects 0.0112762451171875
. 0.046875
▁However 1.357421875
, 0.0002741813659667969
▁anal 2.16015625
yst 0.00019681453704833984
s 0.0015697479248046875
▁ur 5.234375
ge 0.0012359619140625
▁ca 0.4990234375
ution 8.702278137207031e-05
, 3.001953125
▁emphas 2.244140625
izing 0.005573272705078125
▁that 2.837890625
▁further 1.703125
▁expl 6.4140625
oration 0.0228424072265625
, 4.20703125
▁regul 4.47265625
atory 6.568431854248047e-05
▁appro 0.279541015625
val 4.792213439941406e-05
, 0.12152099609375
▁and 0.042724609375
▁additional 6.546875
▁real 5.76953125
- 0.0083465576171875
world 0.03997802734375
▁evidence 3.35546875
▁are 0.39990234375
▁needed 1.6455078125
▁before 1.26171875
▁w 3.46484375
ides 0.0008120536804199219
p 0.0017099380493164062
read 0.0009098052978515625
▁implementation 4.0703125
. 0.457763671875
▁Over 4.4140625
coming 2.49609375
▁regul 2.388671875
atory 0.0003337860107421875
▁hur 0.28271484375
d 2.3603439331054688e-05
les 8.666515350341797e-05
, 1.9443359375
▁pr 1.49609375
icing 0.0002262592315673828
▁challeng 1.87890625
es 3.933906555175781e-06
, 0.01641845703125
▁and 0.0265350341796875
▁establish 4.87890625
ing 0.00015676021575927734
▁different 9.8515625
iation 0.0113067626953125
▁from 2.064453125
▁existing 0.9169921875
▁ther 1.083984375
ap 0.0044403076171875
ies 4.76837158203125e-06
▁will 0.33740234375
▁determine 4.11328125
▁the 0.525390625
▁ult 3.279296875
imate 1.1682510375976562e-05
▁success 0.279541015625
▁of 0.10601806640625
▁T 0.5576171875
um 0.00017142295837402344
oro 0.0009245872497558594
C 0.0004017353057861328
ure 9.608268737792969e-05
. 0.391357421875
▁Nevertheless 5.08203125
, 0.000278472900390625
▁the 1.2353515625
▁initial 5.2734375
▁find 2.69921875
ings 1.0728836059570312e-06
▁offer 3.205078125
▁hope 1.1142578125
▁for 0.5224609375
▁patients 1.171875
, 2.0546875
▁p 4.234375
aving 0.009124755859375
▁the 0.01922607421875
▁way 0.026336669921875
▁for 0.254150390625
▁potential 3.580078125
▁adv 2.646484375
anc 0.28369140625
ements 3.170967102050781e-05
▁in 0.1663818359375
▁cancer 0.452392578125
▁treatment 0.296142578125
▁and 2.322265625
▁transform 7.62890625
ing 0.1878662109375
▁the 0.4765625
▁lives 2.21484375
▁of 0.00408935546875
▁those 1.0029296875
▁affected 0.9208984375
▁by 0.6904296875
▁the 1.3125
▁disease 0.02606201171875
. 0.0231781005859375
